• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohor

tetano

Editor, Senior Moderator
Sci Rep


. 2023 Nov 7;13(1):19322.
doi: 10.1038/s41598-023-46421-4. Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort

Pieter Ruytinx[SUP] #[/SUP][SUP] 1 [/SUP], Patrick Vandormael[SUP] #[/SUP][SUP] 1 [/SUP], Judith Fraussen[SUP] #[/SUP][SUP] 1 [/SUP], Zoë Pieters[SUP] 2 [/SUP], Stef Thonissen[SUP] 3 [/SUP], Niels Hellings[SUP] 1 [/SUP], Piet Stinissen[SUP] 1 4 [/SUP], Ina Callebaut[SUP] 4 5 [/SUP], Joris Penders[SUP] 4 6 [/SUP], Karolien Vanhove[SUP] 4 7 [/SUP], Davy Kieffer[SUP] 8 [/SUP], Jean-Luc Rummens[SUP] 3 4 9 10 [/SUP], Tom Valkenborgh[SUP] 11 [/SUP], Peter Messiaen[SUP] 4 12 [/SUP], Björn Stessel[SUP] 4 5 [/SUP], Dieter Mesotten[SUP] 4 13 [/SUP], Veerle Somers[SUP] 14 15 [/SUP]



Affiliations
Abstract

The immune response in patients with Coronavirus Disease 2019 (COVID-19) is highly variable and is linked to disease severity and mortality. However, antibody and cytokine responses in the early disease stage and their association with disease course and outcome are still not completely understood. In this large, multi-centre cohort study, blood samples of 434 Belgian COVID-19 hospitalized patients with different disease severities (ranging from asymptomatic/mild to critically ill) from the first wave of the COVID-19 pandemic were obtained. Baseline antibody and cytokine responses were characterized and associations with several clinical outcome parameters were determined. Anti-spike immunoglobulin (Ig)G and IgM levels were elevated in patients with a more severe disease course. This increased baseline antibody response however was associated with decreased odds for hospital mortality. Levels of the pro-inflammatory cytokines IL-6, IP-10 and IL-8, the anti-inflammatory cytokine IL-10 and the antiviral cytokines IFN-α, IFN-β and IFN-λ1 were increased with disease severity. Remarkably, we found significantly lower levels of IFN-λ2,3 in critically ill patients compared to patients of the moderate and severe disease category. Finally, levels of IL-8, IL-6, IP-10, IL-10, IFN-α, IFN-β, IFN-γ and IFN-λ1 at baseline were positively associated with mortality, whereas higher IFN-λ2,3 levels were negatively associated with mortality.


 
Back
Top Bottom